PPARgamma-agonist Rosiglitazone Increases Number and Migratory Activity of Cultured Endothelial Progenitor Cells

Atherosclerosis. 2005 Nov;183(1):163-7. doi: 10.1016/j.atherosclerosis.2005.03.039.

Abstract

Objective: Endothelial progenitor cells (EPC) are involved in the process of endothelial maintenance and angiogenesis and might be related to endothelial function. EPC function was shown to be impaired in type 2 diabetic patients. Since endothelial dysfunction of type 2 diabetic patients can be ameliorated by treatment with thiazolidinediones we asked whether this treatment might also influence number and function of EPC.

Methods and results: We investigated 10 recently diagnosed type 2 diabetic patients and 10 age and sex matched healthy control subjects. After baseline examination of metabolic parameters and EPC, patients received 4 mg rosiglitazone b.i.d. for 12 weeks. We measured EPC number and migratory activity after 3 and 12 weeks of treatment. Migratory activity of EPCs obtained from type 2 diabetic patients at baseline was 40% lower compared to control (P<0.05). There was no significant difference of EPC number between patients (323+/-19) and controls (358+/-25) at baseline. Treatment of patients with rosiglitazone normalized impaired migratory activity of EPC and increased EPC number (464+/-33, P<0.01). In addition treatment improved glycemic control and insulin sensitivity.

Conclusions: Twelve-week treatment with rosiglitazone improved EPC number and migratory activity of type 2 diabetic patients. The latter mechanism may contribute to the recently observed improvement of endothelial function by rosiglitazone in type 2 diabetes.

MeSH terms

  • AC133 Antigen
  • Antigens, CD / analysis
  • Antigens, CD34 / analysis
  • Cell Count
  • Cell Division / drug effects
  • Cell Movement / drug effects
  • Cells, Cultured / drug effects
  • Cholesterol / blood
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetes Mellitus, Type 2 / pathology
  • Endothelial Cells / drug effects
  • Endothelium, Vascular / cytology
  • Endothelium, Vascular / drug effects*
  • Female
  • Glucose Clamp Technique
  • Glycated Hemoglobin A / analysis
  • Glycoproteins / analysis
  • Humans
  • Hyperinsulinism / blood
  • Insulin Resistance
  • Lipoproteins, LDL / metabolism
  • Male
  • Middle Aged
  • Monocytes / cytology
  • Monocytes / drug effects*
  • PPAR gamma / agonists*
  • Peptides / analysis
  • Rosiglitazone
  • Single-Blind Method
  • Thiazolidinediones / pharmacology*
  • Thiazolidinediones / therapeutic use
  • Triglycerides / blood
  • Vascular Endothelial Growth Factor A / blood

Substances

  • AC133 Antigen
  • Antigens, CD
  • Antigens, CD34
  • Glycated Hemoglobin A
  • Glycoproteins
  • Lipoproteins, LDL
  • PPAR gamma
  • Peptides
  • Thiazolidinediones
  • Triglycerides
  • Vascular Endothelial Growth Factor A
  • acetyl-LDL
  • Rosiglitazone
  • Cholesterol